OctoPlus' licensee Biolex commences Phase IIb study with Locteron

22-Apr-2009 - USA

OctoPlus N.V. announced that its licensee Biolex Therapeutics has commenced patient dosing in the SELECT-2 Phase IIb clinical study of Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. Locteron combines OctoPlus' controlled release drug delivery technology PolyActive® with Biolex' interferon alpha and is the most advanced product in clinical development incorporating one of OctoPlus' proprietary drug delivery technologies.

In October 2008 OctoPlus entered into an exclusive license and product acquisition agreement with Biolex, worth up to € 100 million. As a result, Biolex holds the full commercial rights to Locteron and is responsible for development and commercialisation, and OctoPlus is paid by Biolex to perform process development and to manufacture Locteron.

The Phase IIb study is being conducted in the United States and Europe in 100 treatment-naïve, genotype-1, chronic hepatitis C patients. Patients will be randomised into one of four dosing cohorts, the 320, 480 or 640 µg dose of Locteron (administered once every two weeks) or a control arm consisting of PEG-Intron® (administered every week), with all patients receiving weight-based ribavirin. Patients will be treated for 48 weeks and will be followed for an additional 24 weeks to determine the sustained virologic response (SVR) rate. The interim results after 12 weeks of treatment are expected to be used as the basis for the selection of the Locteron dose(s) for Phase III studies.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance